Decision

Apotex Inc. v. Pfizer Canada Inc., 2017 FC 951 (Latanoprost*)

2017-10-25

Read full decision. Automatically generated summary:

[Note: This decision is from 2017 but only posted today.] This is a motion by Apotex Inc. to further amend its Amended Reply and Defence to Counterclaim pursuant to Rule 75(1) of the Federal Courts Rules. ... Pfizer argues that with these amendments, Apotex is improperly trying to repackage the arguments related to the Promise Doctrine rejected by the SCC in Esomeprazole.

Decision relates to:

  • T-1064-13 - APOTEX INC. v. PFIZER CANADA INC.

 

Canadian Intellectual Property